A dermatology practice says progress on a GLP-1 is about more than the scale, urging choices that leave patients feeling strong. Light on specifics.
Recap by typeshit. Post by @grossmandermatology on Instagram.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
In 2,749 people with type 2 diabetes, the daily pill also beat insulin on blood sugar and weight, though 62% reported stomach side effects. Results were presented at EASD.
Plastic surgeon Terry Dubrow weighs in on whether peptides are safe in a short clip posted by Howie Mandel. Details are only in the video.
Loading…